Personalized medicine in psoriasis: Concept and applications

Current Vascular Pharmacology

Volumn 8, Issue 3, 2010, Pages 432-436

  Al Hoqail, Ibrahim A ^a  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

Biomarkers; Personalized medicine; Pharmacogenetics; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL MARKER; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RETINOID;

ARTICLE; CHRONIC DISEASE; CLINICAL MEDICINE; COMPREHENSION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUSTRY; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; KNOWLEDGE; NONHUMAN; PHARMACOGENETICS; PHOTOTHERAPY; PHYSICIAN; PREVENTIVE MEDICINE; PROGNOSIS; PSORIASIS; SCREENING; TRAINING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; GENE THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSORIASIS;

EID: 77952906745     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112223     Document Type: Article

References (48)

1. Shorokhov D, Zewail AH. 4D Electron imaging: principles and perspectives. Phys Chem Chem Phys 2008; 10: 2879.
2. Schwartz UI. Clinical relevance of genetic polymorphism in the human CYP2C9 gene. Eur J Clin Invest 2003; 33 (suppl 2): 23-30.
3. Shastry BS. Pharmacogenetics and concept of individualize medicine. Phamacogenomics J 2006; 6: 16-21.
4. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.
5. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Dermatol Venereol 2007; 87: 506-9.
6. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2006; 56: 629-34.
7. Kurd SK, Richardson S, Gelfand JM. Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol 2007; 3: 171-85.
8. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev Dermatol 2006; 1: 63-75.
9. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
10. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20: 416-22.
11. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129(10): 2411-8.
12. Griffiths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
13. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. Eur Heart J 2001; 22: 1226-34.
14. Wei CC, Hsu YH, Li HH, et al. IL-20: biological functions and clinical implications. J Biomed Sci 2006; 13: 601-12.
15. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 273-9.
16. Sabat R, Philipp S, Höflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-98.
17. Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009; 10: 201-9.
18. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Aging-induced pro-inflammatory shift in cytokine expression profile in rat coronary arteries. FASEB J 2003; 17: 1183-5.
19. Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49: 741-52.
20. Bowden DW, Rudock M, Ziegler J, et al. Coincident linkage of type 2 diabetes, metabolic syndrome and measures of cardiovascular disease in a genome scan of the diabetes heart study. Diabetes 2006; 55: 1985-94.
21. Das SK, Elbein SC. The search for type 2 diabetes susceptibility loci: the chromosome 1q story. Curr Diab Rep 2007; 7: 154-64.
22. Ng MC, Miyake K, So WY, et al. The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 2005; 48: 2018-24.
23. Parker A, Meyer J, Lewitzky S, et al. A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. Diabetes 2001; 50: 675-80.
24. Suviolahti E, Lilja HE, Pajukanta P. Unraveling the complex genetics of familial combined hyperlipidemia. Ann Med 2006; 38: 337-51.
25. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39: 770-5.
26. Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohns disease. J Med Genet 2008; 45: 114-6.
27. Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006; 154: 345-52.
28. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
29. Mildvan D, Landlay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997; 24: 764-74.
30. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64: 1137-9.
31. Suomela S, Kainu K, Onkamo P, et al. Clinical associations of the risk alleles of HLA-Cw6 and CHCR1*WWCC in psoriasis. Acta Derm Venereol 2007; 87: 127-34.
32. Barker JN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001; 26: 321.
33. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64: 30-6.
34. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elba i MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159: 180-6.
35. Wang L, Yang L, Gao L, Gao TW, Li W, Liu YF. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with psoriasis. Int J Immunogenet 2007; 35: 45-9.
36. Bhawan J, Bansal C, Whren K, Schwertschlag U. IL-11 Psoriasis Study Group. K16 expression in uninvolved psoriatic skin: a possible marker of pre-clinical psoriasis. J Cutan Pathol 2004; 31: 471-6.
37. Centola M, Frank MB, Bolstad AI, et al. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: a potential breakthrough diagnostic and individualized therapy-design tool. Scand J Immunol 2006; 64: 236-42.
38. Flisiak I, Porebski P, Flisiak R, Chodynicka B. Plasma transforming growth factor 1 as a biomarker of psoriasis activity and treatment efficacy. Biomarker 2003; 5: 437-43.
39. Cristofaro P, Opal SM. Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 2006; 66: 15-29.
40. Hairutdinov VR, Moshkalov AV, Samtsov AV. Apoptosisdeficient Pro allele of p53 gene is associated with the resistance of psoriasis to the UV-based therapy. J Dermatol Sci 2005; 37: 185-7.
41. Warren RB, Chalmers RJ, Griffiths CE, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin Dermatol 2008; 33: 551-4.
42. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis. Br J Dermatol 2008; 158: 558-66.
43. Van de Kerkhof PC. The evolution of the psoriatic lesion. Br J Dermatol 2007; 157: 4-15.
44. Sikora K. Personalized medicine for cancer, from molecular signature to therapeutic choice. Adv Cancer Res 2007; 96: 345-69.
45. Woodcock J. The prospects for 'personalized medicine' in drug development and drug therapy. Clin Pharmacol Ther 2007; 81: 164-9.
46. Future of Family Medicine Project Leadership Committee. The future of family medicine. Ann Fam Med 2004; 2(suppl 1): S3-S32.
47. Food and Drug Administration: Innovation or stagnation: challenges and opportunity on the critical path to new medical products. March 2004. www.fda.gov/oc/initiatives/criticalpath/white-paper.html
48. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007; 81: 807-16.